U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283900) titled 'Ascorbate in Myelodysplastic Syndrome' on Nov. 19.
Brief Summary: This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.
Study Start Date: May 01, 2026
Study Type: INTERVENTIONAL
Condition:
Myelodysplastic Syndromes
Intervention:
DRUG: High-dose ascorbate
Ascorbate, or vitamin C, is a water-soluble vitamin with antioxidant properties that also functions as a cofactor for several enzymatic reactions, including collagen synthesis and the activity of dioxygenase enzymes involved in DNA and histone dem...